Introduction to Cholinesterase Inhibitors
Cholinesterase inhibitors, also known as acetylcholinesterase inhibitors, are chemicals used for the blockage of normal decomposition of acetylcholine. Acetylcholine is another chemical that acts as the main neurotransmitter for both the central as well as the peripheral nervous system. This neurotransmitter is broken down with the help of an enzyme called cholinesterase, and the action of this enzyme is blocked by cholinesterase inhibitors, thereby preventing the breakdown of acetylcholine. This allows more acetylcholine to reach the brain and help with increasing cognition. Cholinesterase inhibitors are primarily used for reducing the symptoms related with disorders such as dementia and Alzheimer’s disease among other neural disorders.
Market Size and Forecast
The cholinesterase inhibitors market is anticipated to record a significantly high CAGR over the forecast period, i.e., 2020-2028. The market is segmented by chemical, by indication, by route of administration and by region, out of which, the chemical segment is further segmented into rivastigmine, donepezil, galantamine and tacrine. Out of these, all cholinesterase inhibitors have been approved by the U.S. Food and Drug Administration (FDA), however, only three of these, i.e., rivastigmine, donepezil and galantamine are sold in the United States. The sale of tacrine has been discontinued.
Based on route of administration, the market is segmented into oral and transdermal. The oral route of administration is anticipated to hold the largest share in the cholinesterase inhibitors market on account of tablets and capsules being the most common dosage form. Based on indication, the market is segmented into Alzheimer’s disease, myasthenia gravis, Parkinson’s disease, dementia, schizophrenia and others. The Alzheimer’s disease segment is predicted to grow at the highest rate as a result of rising cases of the disease which increase the demand for cholinesterase inhibitors in the market. As per the 2019 statistics by the Alzheimer’s Association, Alzheimer’s disease is the most common cause of dementia and accounts for an estimated 60% to 80% of all cases. CLICK TO DOWNLOAD SAMPLE REPORT
Growing Cases of Disorders Associated with Dementia to Drive the Market Growth
According to the Alzheimer’s Association, Alzheimer’s disease is the 6th leading cause of death in the United States, with around 5 million people living with the disorder. Further, it estimates that deaths from heart diseases have decreased by 7.8% between 2000 and 2018. On the other hand, deaths from Alzheimer’s disease have increased by 146% in the country. The growing number of deaths as a result of this disorder is anticipated to increase the demand for drugs that treat the disease or relieve the symptoms of the disorder. On account of this, the market is predicted to grow in the coming years.
Generation of High Revenue Through Approved Drugs to Provide Increased Business Opportunities
The approved cholinesterase inhibitors are available in the market under several brand names which are manufactured and marketed by various leading pharmaceutical companies. The high demand for these drugs is estimated to result in the generation of high revenue, which is further predicted to increase business opportunities in the market.
Limited Availability of Medicines to Restrict the Market Growth
Cholinesterase inhibitors can only be used for reducing the symptoms of dementia and other conditions and not for their cure. This is predicted to limit the demand for these inhibitors in the market in the next few years.
Our in-depth analysis of the cholinesterase inhibitors market includes the following segments:
By Route of Administration
On the basis of regional analysis, the cholinesterase inhibitors market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
The market for cholinesterase inhibitors in North America is estimated to hold the largest share in the market which can be accounted for presence of major leading key players in the industry in this region, especially in the United States. The market in Asia Pacific is predicted to witness highest growth rate over the forecast period as a result of booming demand for medicines for the treatment of dementia and Alzheimer’s disease.
The cholinesterase inhibitors market is further classified on the basis of region as follows:
Top Featured Companies Dominating the Market
Generation of high revenue from approved cholinesterase inhibitors and growing deaths from disorders such as the Alzheimer’s disease are predicted to drive the market growth.
The market is anticipated to attain a high CAGR over the forecast period, i.e. 2020-2028.
North America is anticipated to hold the dominating share in the market.
The market in Asia Pacific will provide more business opportunities as a result of booming demand for medicines for the treatment of dementia and Alzheimer’s disease.
The major players in the market are Novartis, Pfizer, Eisai Co., Ltd, Cadila Pharmaceuticals, Allergan, Cipla Ltd, R&D Systems and Dr. Reddys Laboratories Limited.
Company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization